Overview

Ketamine for Depression: An MRI Study

Status:
Completed
Trial end date:
2017-12-29
Target enrollment:
Participant gender:
Summary
Ketamine has been shown to decrease symptoms of anxious depression quickly. This decrease has been shown to last for up to one month. MRI technology will be used before and after ketamine for patients with depression to examine the extent to which certain brain areas predict ketamine's antidepressant effects.
Phase:
Phase 4
Details
Lead Sponsor:
Massachusetts General Hospital
Collaborators:
Brain & Behavior Research Foundation
National Institutes of Health (NIH)
Treatments:
Ketamine